Literature DB >> 31912094

Immunohistochemical evaluation of tumor budding in colorectal cancer: an important parameter with prognostic value.

Cristian Meşină1, Cătălin Liviu Stoean, Ruxandra Stoean, Adrian Victor Săndiţă, Theodor Viorel Dumitrescu, Stelian Ştefăniţă Mogoantă, Daniel Alin Cristian, Mihaela Iustina Meşină-Botoran, George Mitroi, Corina Lavinia Gruia, Maria Camelia Foarfă, Mihai Meşină, Daniel Ciobanu.   

Abstract

We analyzed 82 patients with colorectal cancer (CRC) [75 patients with mucinous adenocarcinoma (ADK) and seven patients with "signet ring cell" ADK] using multi-cytokeratin (CK) AE1AE3 immunohistochemical assay. In order to determine the mucinous nature of some of the lymph node metastases of the mucinous colorectal ADKs studied, Periodic Acid Schiff-Alcian Blue (PAS-AB) histochemical staining was used. The counting results were systematized in the following ranges: 0 budding areas; between 1-4 budding areas; between 5-9 budding areas; and =10 tumor budding (TB) areas. The statistical analysis was performed using the Student's t-test. More than half of the cases of mucinous ADK revealed an increased intensity of TB, whereas in the case of "signet ring cell" ADK, an average intensity of this phenomenon. Mucinous ADKs, which were pT3 staged, showed an increased intensity of TB, and those in pT2 stage demonstrated, in the vast majority of cases, the absence of TB. There was a predominance of TB intensity in the absence of vascular-lymphatic invasion. Our study shows the existence of a concordance between tumor progression, the histological type of CRC, vascular-lymphatic invasion and the phenomenon of TB.

Entities:  

Mesh:

Year:  2019        PMID: 31912094

Source DB:  PubMed          Journal:  Rom J Morphol Embryol        ISSN: 1220-0522            Impact factor:   1.033


  1 in total

Review 1.  From Dukes-MAC Staging System to Molecular Classification: Evolving Concepts in Colorectal Cancer.

Authors:  Laura Banias; Ioan Jung; Rebeca Chiciudean; Simona Gurzu
Journal:  Int J Mol Sci       Date:  2022-08-21       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.